FCM
CYTK icon

Farallon Capital Management’s Cytokinetics CYTK Stock Holding History

Farallon Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-102,400
Closed -$5.41M – 159
2024
Q3 		$5.41M Hold
102,400
– – 0.02% 95
2024
Q2 		$5.55M Hold
102,400
– – 0.02% 91
2024
Q1 		$7.18M Sell
102,400
-985,372
-91% -$76.2M 0.03% 98
2023
Q4 		$90.8M Buy
1,087,772
+1,066,000
+4,896% +$38.6M 0.42% 48
2023
Q3 		$641K Hold
21,772
– – ﹤0.01% 116
2023
Q2 		$710K Sell
21,772
-916,300
-98% -$33.9M ﹤0.01% 127
2023
Q1 		$33M Sell
938,072
-763,666
-45% -$31.2M 0.18% 70
2022
Q4 		$78M Buy
1,701,738
+80,700
+5% +$3.47M 0.46% 53
2022
Q3 		$78.5M Sell
1,621,038
-624,000
-28% -$30M 0.43% 62
2022
Q2 		$88.2M Buy
2,245,038
+362,439
+19% +$14.6M 0.48% 58
2022
Q1 		$69.3M Sell
1,882,599
-287,743
-13% -$10.2M 0.33% 62
2021
Q4 		$98.9M Sell
2,170,342
-562,433
-21% -$21.7M 0.49% 49
2021
Q3 		$97.7M Sell
2,732,775
-143,225
-5% -$4.22M 0.46% 55
2021
Q2 		$56.9M Buy
2,876,000
+376,000
+15% +$8.83M 0.23% 68
2021
Q1 		$58.1M Buy
2,500,000
+100,000
+4% +$2.14M 0.29% 66
2020
Q4 		$49.9M Buy
2,400,000
+250,000
+12% +$4.57M 0.3% 63
2020
Q3 		$46.5M Buy
2,150,000
+650,000
+43% +$15.2M 0.32% 66
2020
Q2 		$35.4M Buy
1,500,000
+875,000
+140% +$16.4M 0.28% 66
2020
Q1 		$7.37M Buy
+625,000
New +$7.97M 0.06% 86

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Farallon Capital Management's CYTK Position: Q4 2024 in Review

Farallon Capital Management sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 102,400 shares — an estimated $5.41M sold.

Farallon Capital Management first reported a position in CYTK in Q1 2020 and held it in 19 quarters. The position peaked at $98.9M in Q4 2021. 346 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

  • Farallon Capital Management reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
  • Farallon Capital Management sold 102,400 Cytokinetics shares in Q4 2024, an estimated $5.41M.
  • Farallon Capital Management first reported a position in Cytokinetics in Q1 2020 and held it in 19 quarters.
  • Farallon Capital Management's Cytokinetics position peaked at $98.9M in Q4 2021.
  • 346 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on Farallon Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.